Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

Launched by LIAQUAT UNIVERSITY OF MEDICAL & HEALTH SCIENCES · Dec 27, 2024

Keywords

ClinConnect Summary

The study investigates the ability of AHCC® (Active Hexose Correlated Compound) to support immune modulation and promote negativity of persistent HPV infections, which are associated with an increased risk of cervical cancer. Participants are categorized into three groups based on vaccination and supplement use. Outcomes include the proportion of participants achieving HPV negativity and the safety and tolerability of the supplement over a 4-6 month period. The study aims to evaluate the potential of AHCC® as a complementary approach for managing persistent HPV infection.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female participants aged 18 years or older.
• • Persistent HPV infection for at least 6 continuous months, confirmed by DNA-HPV testing.
• • No prior treatment for cervical lesions via conization.
• • No prior HPV vaccination
• Exclusion Criteria:
• • Current or planned pregnancy during the study period.
• • Immunocompromised status, including known HIV infection.
• • Severe or high-grade cervical lesions.
• • Known allergy or hypersensitivity to AHCC® or vaccine components.